Welcome to our dedicated page for Jade Biosciences news (Ticker: JBIO), a resource for investors and traders seeking the latest updates and insights on Jade Biosciences stock.
Jade Biosciences develops monoclonal antibody therapies for autoimmune diseases, with company updates centered on clinical execution, pipeline expansion, and financing. Its lead program, JADE101, targets APRIL and is being developed for immunoglobulin A nephropathy; additional programs include JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, and JADE301, an antibody program in preclinical development.
Recurring news includes financial results, corporate updates, clinical and biomarker data presentations, research conference participation, private placement financing, equity inducement grants, and leadership changes tied to the company's research and development organization.
Jade Biosciences (Nasdaq: JBIO), a clinical-stage biotech focused on autoimmune diseases, will participate in several September 2026 investor and healthcare conferences, including fireside chats at Wells Fargo (Sept 8, 3:45 p.m. ET), Citi (Sept 9, 9:20 a.m. ET), H.C. Wainwright (Sept 15, 1:00 p.m. ET) and the Stifel Virtual Immunology and Inflammation Forum (Sept 23, 10:30 a.m. ET).
Jade management will also hold one-on-one investor meetings, and live webcasts of the Wells Fargo, Citi and H.C. Wainwright sessions will be available on the company’s website, with replays accessible for 90 days.
Jade Biosciences (Nasdaq: JBIO) reported second quarter 2026 results and major pipeline progress, highlighted by positive interim Phase 1 data for JADE101 in IgA nephropathy showing ~70% mean IgA reduction after a single 700 mg dose, durable biomarker effects supporting potential 12‑week subcutaneous maintenance dosing, and favorable tolerability.
The company has begun a Phase 2 JADE101 IgAN trial with interim data expected in 2027 and plans a registrational Phase 3 in 1H 2027, pending FDA feedback. Dosing began in a Phase 1 trial of JADE201 in rheumatoid arthritis, with biomarker‑rich data expected in 2027.
Jade unveiled JADE301 for dermatomyositis, aiming to start a Phase 1 healthy volunteer trial in Q4 2026 with interim data in 2H 2027. The company completed a $172.5 million public offering and ended June 30, 2026 with $461.2 million in cash, cash equivalents and investments, which it expects will fund operations into Q4 2028. Q2 2026 R&D expenses were $50.1 million, G&A expenses were $8.9 million, and net loss was $55.8 million.
Jade Biosciences (Nasdaq: JBIO), a clinical-stage biotechnology company developing antibody-based therapies for autoimmune diseases, appointed Mark Eisner, M.D., M.P.H. to its Board of Directors, effective June 25, 2026.
Dr. Eisner brings over 25 years of leadership in clinical development and immunology, including senior roles at Vir Biotechnology, Sonoma Biotherapeutics, FibroGen, and Genentech/Roche.
Jade Biosciences (Nasdaq: JBIO) closed a public offering of 11,500,000 common shares, including 1,500,000 from full exercise of underwriters’ option, at $15.00 per share.
The deal generated $172.5 million in gross proceeds to fund clinical trials, preclinical studies, manufacturing, R&D, capital spending, and general corporate purposes.
Jade Biosciences (Nasdaq: JBIO) priced a public offering of 10,000,000 common shares at $15.00 per share, for expected gross proceeds of $150 million before expenses. Underwriters have a 30-day option for up to 1,500,000 extra shares.
According to Jade Biosciences, net proceeds plus existing cash will fund clinical trials, preclinical studies, manufacturing, R&D, capital expenditures, working capital and general corporate purposes. The offering is expected to close on June 5, 2026, subject to customary conditions.
Jade Biosciences (Nasdaq: JBIO) plans a proposed underwritten public offering of common stock and, for certain investors, pre-funded warrants to buy common shares. All securities will be sold by Jade, with underwriters receiving a 30-day option for up to 15% additional securities. Proceeds are intended to fund clinical trials, preclinical studies, manufacturing, R&D, capital spending, working capital and general corporate purposes.
Jade Biosciences (Nasdaq: JBIO) reported positive interim Phase 1 results for JADE101, an anti-APRIL antibody for IgA nephropathy. A single 700 mg dose produced ~70% mean IgA reduction sustained at 12 weeks with favorable tolerability and no serious adverse events.
Modeling suggests >70% IgA reductions at steady state using a 700 mg induction followed by 350 mg subcutaneous maintenance dosing every 12 weeks. Phase 2 in IgAN is underway, with interim data expected in 2027 and a Phase 3 trial planned for the first half of 2027.
Jade Biosciences (Nasdaq: JBIO) will host a conference call and webcast on June 1, 2026, at 8:00 a.m. ET to discuss interim Phase 1 healthy volunteer results for JADE101, an anti-APRIL monoclonal antibody in development for IgA nephropathy.
Jade Biosciences (Nasdaq: JBIO) has dosed the first participant in a first-in-human Phase 1 trial of JADE201, an investigational half-life extended afucosylated anti-BAFF receptor monoclonal antibody for rheumatoid arthritis.
The randomized, placebo-controlled single ascending dose study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarkers, with interim data expected in 2027. Preclinical data showed dose-dependent BAFF-R occupancy, extended half-life, and sustained B cell depletion in non-human primates, supporting potential for infrequent subcutaneous dosing across autoimmune diseases.
Jade Biosciences (Nasdaq: JBIO) dosed the first participant in JUNIPER, its open-label Phase 2 trial of JADE101 for IgA nephropathy (IgAN). The study will enroll about 30 participants and assess safety, urine protein-to-creatinine ratio, renal function, and hematuria.
Interim Phase 2 data are expected in 2027.